MedTrace Logo

Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects

NCT01520831 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2017-01-04

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to demonstrate a difference between the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in healthy subjects.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

DRUG

biphasic insulin aspart 50

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

DRUG

biphasic insulin aspart 70

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

DRUG

insulin aspart

One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Primary Completion
2000-05-31
Completion
2000-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01520831 on ClinicalTrials.gov